University of Vermont Medical Center
Hematology and Oncology fellowship · Burlington, VT · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Vermont Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About University of Vermont Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from University of Vermont Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
25
works per year
64th of 74 hematology and oncology fellowship programs
+14.9%
2-year growth
30th of 74 hematology and oncology fellowship programs
16.4%
in top 10% of field (works before 2025)
57th of 72 hematology and oncology fellowship programs
38.4%
cited above world average
49th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 75Hematology · 44
Hematology and Oncology research topics at University of Vermont Medical Center
Papers in the window; each links to the list on OpenAlex.
Most cited at University of Vermont Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda et al. · New England Journal of Medicine · 2025 · PubMed · cited 131
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin M. Kalinsky et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 101
- Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohortAnwaar Saeed et al. · Nature Communications · 2024 · PubMed · cited 54
- Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L. Jhaveri et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 52
- Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium CohortDiana L. Miglioretti et al. · Annals of Internal Medicine · 2024 · PubMed · cited 38
- Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A ReviewSimran Kalsi et al. · Current Oncology Reports · 2024 · PubMed · cited 24
- Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed et al. · Blood Advances · 2025 · PubMed · cited 21
- Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohortJacqueline N. Poston et al. · Blood Advances · 2024 · PubMed · cited 20
- The association of chemotherapy-induced peripheral neuropathy with reduced executive function in chemotherapy-treated cancer survivors: A cross-sectional studyBrendan L. McNeish et al. · Journal of Geriatric Oncology · 2024 · PubMed · cited 12
- Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice GuidelineChristopher James Anker et al. · Practical Radiation Oncology · 2025 · PubMed · cited 10